Acecarbromal

Acecarbromal
Names
	Preferred IUPAC name N-(Acetylcarbamoyl)-2-bromo-2-ethylbutanamide
	Other names 1-Acetyl-3-(2-bromo-2-ethylbutyryl)urea
Identifiers
CAS Number	77-66-7 ;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL2104673;
ChemSpider	6244 ;
ECHA InfoCard	100.000.953
EC Number	201-047-1;
KEGG	D07059 ;
MeSH	acecarbromal
PubChem CID	6489;
UNII	E47C56IGOY ;
CompTox Dashboard (EPA)	DTXSID9058810 ;
	InChI InChI=1S/C9H15BrN2O3/c1-4-9(10,5-2)7(14)12-8(15)11-6(3)13/h4-5H2,1-3H3,(H2,11,12,13,14,15) Key: SAZUGELZHZOXHB-UHFFFAOYSA-N ;
	SMILES CCC(Br)(CC)C(=O)NC(=O)NC(C)=O;
Properties
Chemical formula	C9H15BrN2O3
Molar mass	279.134 g·mol−1
Pharmacology
Routes of; administration	Oral
Legal status	In general: ℞ (Prescription only);
Related compounds
Related compounds	Buformin; Methylarginine; Asymmetric dimethylarginine; N-Propyl-L-arginine;
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Acecarbromal (INN) (brand names Sedamyl, Abasin, Carbased, Paxarel, Sedacetyl, numerous others), also known as acetylcarbromal and acetyladalin, is a hypnotic and sedative drug of the ureide (acylurea) group discovered by Bayer in 1917^[1] that was formerly marketed in the United States and Europe.^[2]^[3] It is also used in combination with extract of quebracho and vitamin E as a treatment for erectile dysfunction under the brand name Afrodor in Europe.^[4]^[5]^[6] Acecarbromal is structurally related to the barbiturates, which are basically cyclized ureas.^[7] Prolonged use is not recommended as it can cause bromine poisoning.^[7]

^ DE 327129, "Verfahren zur Darstellung von Derivaten bromacylierter Harnstoffe (Procedures for the preparation of derivatives of bromoacylated urea)", issued 5 October 1920, assigned to Bayer AG
^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 2–. ISBN 978-1-4757-2085-3.
^ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 4–. ISBN 978-3-88763-075-1.
^ Muller NF, Dessing RP, eds. (19 June 1998). European Drug Index: European Drug Registrations, Fourth Edition. CRC Press. pp. 36–. ISBN 978-3-7692-2114-5.
^ Baumbusch F, Papp GK, Kopa ZS (1995). "Treatment for potency problems with Afrodor 2000". Acta Chirurgica Hungarica. 35 (1–2): 87–92. PMID 8659243.
^ Sperling H, Lümmen G, Luboldt HJ, Rübben H (January 1999). "[Secondary erectile dysfunction. Is oral medication in the diagnostic phase indicated?]". Der Urologe. Ausg. A. 38 (1): 56–9. doi:10.1007/s001200050246. PMID 10081103. S2CID 24907635.
^ ^a ^b Williams DA, Foye WO, Lemke TL (January 2002). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 380–. ISBN 978-0-683-30737-5.

[1] DE 327129, "Verfahren zur Darstellung von Derivaten bromacylierter Harnstoffe (Procedures for the preparation of derivatives of bromoacylated urea)", issued 5 October 1920, assigned to Bayer AG

[Elks2014-2] Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 2–. ISBN 978-1-4757-2085-3.

[3] Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 4–. ISBN 978-3-88763-075-1.

[Muller1998-4] Muller NF, Dessing RP, eds. (19 June 1998). European Drug Index: European Drug Registrations, Fourth Edition. CRC Press. pp. 36–. ISBN 978-3-7692-2114-5.

[5] Baumbusch F, Papp GK, Kopa ZS (1995). "Treatment for potency problems with Afrodor 2000". Acta Chirurgica Hungarica. 35 (1–2): 87–92. PMID 8659243.

[6] Sperling H, Lümmen G, Luboldt HJ, Rübben H (January 1999). "[Secondary erectile dysfunction. Is oral medication in the diagnostic phase indicated?]". Der Urologe. Ausg. A. 38 (1): 56–9. doi:10.1007/s001200050246. PMID 10081103. S2CID 24907635.

[WilliamsFoye2002-7] Williams DA, Foye WO, Lemke TL (January 2002). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 380–. ISBN 978-0-683-30737-5.

[1]

[2]

[3]

[4]

[5]

[6]

[7]